Leo Pharma Gets Patient-Centric On The Frontiers Of Psoriasis
This article was originally published in The Pink Sheet Daily
Denmark’s dermatology specialist Leo Pharma has linked up with a U.S. psoriasis patient group, the National Psoriasis Foundation, to target innovation on unmet clinical needs.
You may also be interested in...
Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.
Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.
Besides the latest acquisition in the hepatitis C space, the week of the JP Morgan Healthcare Conference saw a spate of deals, including Shire doubling down on its bet on GI drug Resolor and Pfizer inking a pair of deals.